Bristol-Myers Squibb Company (BMY) Is Driving Growth Through Strategic Acquisitions
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
US Federal Judge Dismisses $6.4 Billion Suit Against Bristol Myers Squibb
Bristol Myers Squibb Marks 10 Years of Global Patient Week With Community Initiatives in the Region
U.S. stock market anomaly | Prime Medicine soared about 45%, signed a research collaboration and license agreement with bristol-myers squibb.
September 30th, Gelonghui | Prime Medicine (PRME.US) surged by about 45%, reaching a peak of $5.02. On the news front, Prime Medicine signed a research collaboration and licensing agreement with Bristol-Myers Squibb, agreeing to jointly develop and commercialize multiple therapies. According to the agreement, Bristol-Myers Squibb will invest $55 million to purchase Prime's equity, and Prime will receive a $55 million upfront payment. Once certain sales and development milestones are reached, the upfront payment could exceed $3.5 billion.
Sector Update: Health Care Stocks Steady Premarket Monday
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Powell's Speech on Economic Outlook
Traders Consolidate Positions in Final Session for Q3, Driving Cautious Losses for US Equity Futures
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Sector Update: Health Care
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Express News | Prime Medicine Shares up 15% Premarket on License Agreement With Bristol Myers Squibb for T-Cell Therapies
Prime Medicine Announces Strategic Research Collaboration and License Agreement With Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
US FDA Allows Trial of Sichuan Biokin Pharma-Bristol-Myers Squibb's Cancer Drug
BMO Capital raises bristol-myers squibb's target price to $53.
September 29th, GleAnn | BMO Capital: BMO Capital: raised bristol-myers squibb's target price from $48 to $53, maintaining a 'market perform' rating.
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Daily short sale tracking: Ambev SA's short volume increased by 4 million, with a short sale ratio of 10%
Ambev SA(ABEV.US) ranked top of the list had the largest change in short volume (4.72 million shares), and the short volume ratio of Carnival(CUK.US) reached 39.75%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
US stocks close | US PCE inflation cools down, S&P Nasdaq falls but Dow hits new high; China concept index surges 24% for the whole week, jd.com hits fourteen-month high.
US PCE inflation cooling solidifies the confidence of the Fed in rate cuts, but US stocks fell in the afternoon, with nvidia dropping nearly 4% at one point. China's stimulus policies drove the Chinese concept index up by 4%, nio inc rose by nearly 13%, pan-European stock indexes and German stocks hit new highs for two consecutive days, luxury goods stocks rose again. The Dow, S&P, and Nasdaq have all risen for three consecutive weeks, with two China-focused ETFs achieving the best weekly gains in history.
Express News | The Food and Drug Administration (FDA) of the USA has approved Bristol-Myers Squibb's Cobenfy (xanomeline).